Biosite receives revised commitment letters from Inverness

Biosite’s board of directors will review and evaluate the new information provided by Inverness.

As previously reported, a subsidiary of Beckman Coulter has commenced a cash tender offer to acquire all of the outstanding shares of common stock of Biosite for $85.00 per share. Unless the Beckman Coulter tender offer is extended, it and any withdrawal rights to which Biosite’s stockholders may be entitled will expire on April 27, 2007.

The Biosite board has not withdrawn or amended its recommendation with respect to the Beckman Coulter tender offer, and the merger agreement remains in effect. However Biosote said last week it was prepared to enter into talks with Inverness, which it believed could better an offer from Beckman Coulter.